Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesHonokiol-mediated Inhibition of PI3K/mTOR Pathway: A Potential Strategy to Overcome Immunoresistance in Glioma, Breast, and Prostate Carcinoma Without Impacting T Cell Function
Journal of Immunotherapy, 06/24/09
Crane C et al. - Data define a unique application for Honokiol and provide the impetus to more fully elucidate the mechanism by which T cells are resistant to the effects of this particular inhibitor. Honokiol is clinically available for human testing and may serve to augment T cell-mediated cancer immunotherapy.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/23/09
Update of the guidelines for lupus anticoagulant detection
Journal of Thrombosis and Haemostasis, 09/28/09
Romiplostim in chronic immune thrombocytopenic purpura
Clinical Therapeutics, 10/23/09
Today in Nephrology/Urology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/23/09
Mycophenolate Mofetil Reduces Late Renal Allograft Loss Independent of Acute Rejection
Transplantation, 10/29/09
T Cell–Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective
Clinical Cancer Research, 10/26/09
Sponsor
Article Search
Sponsor